Q-omics provides the consensus-scored SNORD65C profile across patient tissues and cancer cell-line models. SNORD65C expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORD65C is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, SNORD65C RNA expression shows 15,590 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, LUSC, and GBM as cancer lineages where SNORD65C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD65C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD65C survival associations across molecular data types. SNORD65C RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD65C RNA expression–survival associations across cancer types. High SNORD65C expression shows unfavorable associations in KICH, UCEC, SKCM, HNSC and BRCA, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORD65C RNA expression.
This table summarizes SNORD65C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD65C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD65C shows higher tumor expression in LUSC, ESCA, STAD and LUAD. The LUSC box plot shows higher SNORD65C RNA expression in tumor versus normal tissue (log2 FC = +0.443, t-test p < 0.001).
This table shows molecular features associated with SNORD65C in patient tissues and cancer cell lines. In patient samples, SNORD65C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
